These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8173194)

  • 1. [Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers].
    de Forni M; Gualano V; Canal P; Martel P; Izar-Soum F; Chevreau C; Soulié P; Roché H; Bugat R
    Bull Cancer; 1993 May; 80(5):408-17. PubMed ID: 8173194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.
    Newman EM; Akman SA; Harrison JS; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Somlo G; Ahn CW; Doroshow JH
    Cancer Res; 1992 May; 52(9):2408-12. PubMed ID: 1568210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
    Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
    Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer.
    Howell JD; Warren HW; Anderson JH; Kerr DJ; McArdle CS
    Eur J Surg; 1999 Jul; 165(7):652-8. PubMed ID: 10452259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.
    Yeh KH; Cheng AL; Lin MT; Hong RL; Hsu CH; Lin JF; Chang KJ; Lee PH; Chen YC
    Anticancer Res; 1997; 17(5B):3867-71. PubMed ID: 9427794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
    Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
    Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
    Guthoff I; Lotspeich E; Fester C; Wallin I; Schatz M; Ehrsson H; Kornmann M
    Anticancer Res; 2003; 23(6D):5203-8. PubMed ID: 14981990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer.
    Seymour MT; Trigonis I; Finan PJ; Halstead F; Dunham R; Wilson G; Farrugia D; Chester JD; King J; Brown CB; Slevin ML; Joel SP
    Eur J Surg Oncol; 2008 Apr; 34(4):403-9. PubMed ID: 17604939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.